Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany

Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommoss F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15.